Ontology highlight
ABSTRACT:
SUBMITTER: Gonzalez-Ericsson PI
PROVIDER: S-EPMC9547979 | biostudies-literature | 2022 Oct
REPOSITORIES: biostudies-literature
Gonzalez-Ericsson Paula I PI Servetto Alberto A Formisano Luigi L Sánchez Violeta V Mayer Ingrid A IA Arteaga Carlos L CL Sanders Melinda E ME
Applied immunohistochemistry & molecular morphology : AIMM 20220912 9
Clinical trials in patients with ER+ breast cancer with or without FGFR pathway somatic alterations have shown limited clinical benefit from treatment with FGFR tyrosine kinase inhibitors alone or in combination with endocrine therapy. This is likely because of an inadequate predictive biomarker to select appropriate patients. In this study, we evaluated 4 anti-FGFR1 antibodies in breast cancer cell lines and patient-derived xenografts with FGFR1 amplification. We correlated D8E4 expression in 2 ...[more]